{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070346","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.836668+00:00","generated_at":"2026-05-21T13:22:54.984034+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ClearPoint Neuro reports record Q1 revenue $8.5M, consumables up 104% YoY","bullets":["Q1 revenue $8.5M (record), up 11% YoY; consumable product revenue grew 104% to $5.5M.","Neurosurgery navigation therapy revenue up 70% to $3.3M; biologics & drug delivery revenue up 9% to $4.7M.","Gross margin 60% (vs 59%); opEx up 29% to $11.3M on higher R&D and headcount.","Cash $12.4M at Mar 31 (down from $20.1M Dec 2024); credit facility secured with Oberland Capital.","FY 2025 revenue guidance reaffirmed at $36M-$41M; FDA clearance for ClearPoint 3.0 software."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070346","json":"https://secwatch.observer/filing/0000950170-25-070346.json","markdown":"https://secwatch.observer/filing/0000950170-25-070346.md","text":"https://secwatch.observer/filing/0000950170-25-070346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000095017025070346/0000950170-25-070346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000095017025070346/clpt-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T13:22:54.984034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}